Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STSA-1002 in Acute Respiratory Distress Syndrome
NCT07208591Phase 3Recruiting
- Sponsor
- Staidson Biopharmaceutical
- Start
- Oct 2025
- Primary completion
- Jul 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of STSA-1002 in acute respiratory distress syndrome (ARDS), sponsored by Staidson Biopharmaceutical. Started Oct 2025; status: recruiting.
02
Drugs
STSA-1002
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT07208591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208591.